Aggressive cost-saving initiatives and digital transformation are set to drive lasting margin expansion, with strategic focus on sustainable technologies and resilient production supporting robust earnings growth. However, rising regulatory costs, required environmental upgrades, and green competition threaten margins, while dependence on shrinking European markets limits growth prospects.
Cyborg Score Rationale
Evonik remains a fundamentally strong specialty chemicals company, now trading at attractive valuations despite recent earnings downgrades. The company faces headwinds from profitability challenges, but cost initiatives and sustainable product focus offer upside potential.
Top Insights
Trailing 12-month revenue of $15.7B as of September 2025
Dividend yield of 6.25%, supported by long-term dividend history
Five-year net income decline of 26% indicating profitability headwinds
Rising regulatory costs and environmental upgrade requirements pressuring margins
Named Competitors
Wacker Chemie — Specialty chemicals and polymers
BASF — Integrated chemical company
Lanxess — Specialty chemicals
Clariant — Specialty chemicals and materials
Recent Developments
(February 2026) Mixed analyst sentiment with Kepler Capital maintaining sell rating; Deutsche Bank and Warburg Research holding neutral stance
(December 2024) Joint venture with Evonik Fuhua New Materials (Sichuan) in China
(2025) Adjusted financial outlook reflecting market challenges and demand shifts
Open the full interactive Evonik Industries AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.